Plus Therapeutics Has Completed Dosing In Cohort 5 Of ReSPECT-LM Phase 1 Dose Escalation Trial Of Rhenium (186Re) Obisbemeda For Leptomeningeal Metastases From Solid Tumors; Company Expects Moving Into Cohort 6 In Q2 2024 Following Standard Safety Review
Plus Therapeutics已经完成了Rhenium(186Re)Obisbemeda针对实体瘤轻脑膜转移的第5组Rhenium(186Re)1期剂量递增试验;该公司预计在标准安全审查后将于2024年第二季度进入第6队列